VSL#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo‐Controlled, Double‐Blind, Crossover Study
- 1 July 2010
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 51 (1), 24-30
- https://doi.org/10.1097/mpg.0b013e3181ca4d95
Abstract
Background and Objectives: Irritable bowel syndrome (IBS) is a common problem in pediatrics, for which no safe and effective treatment is available. Probiotics have shown some promising results in adult studies, but no positive study has been published on pediatric age. We aimed at investigating the efficacy of VSL#3 in a population of children and teenagers affected by IBS, in a randomized, double-blind, placebo-controlled, crossover study conducted in 7 pediatric gastroenterology divisions. Patients and Methods: Children 4 to 18 years of age, meeting eligibility criteria, were enrolled. The patients were assessed by a questionnaire for a 2-week baseline period. They were then randomized to receive either VSL#3 or a placebo for 6 weeks, with controls every 2 weeks. At the end, after a "wash-out" period of 2 weeks, each patient was switched to the other group and followed for a further 6 weeks. Results: A total of 59 children completed the study. Although placebo was effective in some of the parameters and in as many as half of the patients, VSL#3 was significantly superior to it (P < 0.05) in the primary endpoint, the subjective assessment of relief of symptoms; as well as in 3 of 4 secondary endpoints: abdominal pain/discomfort (P < 0.05), abdominal bloating/gassiness (P < 0.05), and family assessment of life disruption (P < 0.01). No significant difference was found (P = 0.06) in the stool pattern. No untoward adverse effect was recorded in any of the patients. Conclusions: VSL#3 is safe and more effective than placebo in ameliorating symptoms and improving the quality of life in children affected by IBS. © 2010 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and NutritionKeywords
This publication has 26 references indexed in Scilit:
- Probiotics and Irritable Bowel SyndromeJournal of Clinical Gastroenterology, 2008
- Double-blind Placebo-Controlled Trial of Amitriptyline for the Treatment of Irritable Bowel Syndrome in AdolescentsThe Journal of Pediatrics, 2008
- Meta-analysis of probiotics for the treatment of irritable bowel syndromeWorld Journal of Gastroenterology, 2008
- Almost All Irritable Bowel Syndromes Are Post-Infectious and Respond to Probiotics: Consensus IssuesDigestive Diseases, 2007
- Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to dateNeurogastroenterology & Motility, 2006
- The Use of Lactobacillus GG in Irritable Bowel Syndrome in Children: A Double-blind Randomized Control TrialThe Journal of Pediatrics, 2005
- A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloatingNeurogastroenterology & Motility, 2005
- Subject's Global Assessment of Relief: An appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trialsJournal of Clinical Epidemiology, 2003
- Bacterial supplementation in the irritable bowel syndrome. A randomised doubleblind placebo-controlled crossover studyDigestive and Liver Disease, 2000
- Abdominal pain and irritable bowel syndrome in adolescents: A community-based studyThe Journal of Pediatrics, 1996